Participated · Series B · Oct 2025

Founded in 2020 by immunologists Dr. Yang Liu and Dr. Pan Zheng, OncoC4 leverages deep immuno-oncology expertise to create a pipeline of innovative biologic therapies with first-in-class or best-in-class potential. The Rockville, Maryland company is advancing multiple clinical-stage candidates that target both novel and well-validated pathways across oncology and immunological disorders. Its strategy centers on rigorous global clinical development complemented by active business development to broaden therapeutic reach. Although specific revenue or patient metrics were not disclosed, the company characterizes itself as having a broad pipeline poised for growth. Proceeds from its latest financing will fund continued clinical development of these pipeline programs. Management emphasizes a commitment to delivering disruptive therapies to patients worldwide. The company’s leadership team includes Dr. Yang Liu, who serves as Chairman, CEO, and CSO.

Participated · Series A · Sep 2025

Rapafusyn develops non-degrading macrocyclic molecular glues, branded RapaGlues, to address challenging therapeutic targets. Its platform includes DNA-encoded libraries (DELs) and arrayed libraries of RapaGlues that form neo-protein-protein interactions to inhibit target proteins. The compounds are rationally designed to bind FKBP and form ternary complexes with disease target proteins, enabling modulation of intricate protein-protein interactions. The platform’s modular architecture supports SAR and optimization for potency, selectivity, and physicochemical properties to accelerate drug discovery. RapaGlues frequently exhibit cell permeability from the starting point, enhancing their therapeutic potential. The company is led by President and CEO Dr. Sean Hu and intends to use new funding to expand operations and advance its development efforts. Rapafusyn Pharmaceuticals develops non-degrading macrocyclic molecular glues (RapaGlues™) designed to form neo-protein–protein interactions and inhibit target proteins by binding FKBP and creating ternary complexes. The company has built both DNA-encoded libraries (DELs) and arrayed libraries of RapaGlues™ to generate chemical starting points for difficult targets. Its modular architecture enables SAR and optimization for potency, selectivity, and physicochemical properties, and many starting points frequently exhibit cell permeability. Rapafusyn focuses on macrocyclic peptide-based RapaGlues™ as a platform approach to address challenging therapeutic targets. The company plans to use new funding to accelerate progress across its pipeline and to further enhance internal capabilities. Rapafusyn was founded by Jun O. Liu and is headquartered in Baltimore, MD.

Led · Series A · Aug 2025

Arnatar Therapeutics emerged from stealth to advance RNA-based therapeutics using its proprietary platforms, including the ACT-UP1 platform for upregulating protein expression and the DARGER™ platform that combines siRNA with upregulating ASOs. Its lead candidate, ART4, is an up‑regulating antisense oligonucleotide designed to increase endogenous JAG1 protein expression and is administered subcutaneously with once‑monthly dosing. In preclinical studies ART4 increased JAG1 protein levels, restored bile duct development, and reduced markers of liver injury (including bile acids and ALT) in a validated Alagille Syndrome mouse model; it was well tolerated in adult and newborn animals. The company plans to use its new funding to advance the DARGER™ platform and a pipeline targeting cardiometabolic, liver, CNS, and kidney diseases. Arnatar was founded in 2022, received seed financing from Apricot Capital, and is based in San Diego, CA.

Participated · Series B · May 2025

Acclaro Medical builds medical aesthetic devices centered on its UltraClear® 2910 nm cold ablative fiber laser, powered by proprietary 3DIntelliPulse™ technology, and the AuraLux™ system that leverages Cool Pulse™ technology. The UltraClear platform is positioned to treat multiple skin layers with claims of improved safety across all skin types, reduced downtime, and faster healing; the company also markets 3DMIRACL™ and Laser Coring™ skin‑rejuvenation treatments. Acclaro intends to use recent financing to accelerate commercial expansion, advance product development, grow its team, and expand global market reach. The company emphasizes clinical efficacy and broader accessibility for aesthetic providers as core commercial messages. Acclaro was founded in 2018 and frames its roadmap around bringing additional pipeline products to market while scaling adoption of UltraClear and AuraLux. The business announced a material capital infusion in May 2025 to support these plans.

Led · Series B · Jun 2024

赛桥生物 is a biotechnology service provider whose main businesses include biotechnology, medical technology, natural science research and experimental development, and medical-technology R&D. The company recently completed a B round financing of nearly ¥200 million RMB. The round was led by 本草资本, with 弘盛资本 participating as a follow-on investor. Existing shareholders 水木创投, 腾业创投, 昌发展 and 深圳天使母基金 also continued to increase their investments in this round. The company said the financing will be used to accelerate the commercialization of new-quality production equipment. The report was published by DoNews on 2024-06-14 (sourced from IT桔子).